Enarodustat is an orally active factor inhibitor of prolyl hydroxylase (EC50: 0.22 μM) and has the potential for renal anemia treatment.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 77 | |
4 mg | In stock | $ 138 | |
8 mg | In stock | $ 220 | |
20 mg | In stock | $ 403 | |
40 mg | In stock | $ 624 |
Description | Enarodustat is an orally active factor inhibitor of prolyl hydroxylase (EC50: 0.22 μM) and has the potential for renal anemia treatment. |
Targets&IC50 | factor prolyl hydroxylase:(EC50)0.22 μM |
In vitro | Enarodustat exhibits neither CYP (IC50 > 100 μM; CYP3A4/5, CYP2C9, CYP2D6, CYP1A2, CYP2A6, CYP2C19, CYP2C8, CYP2B6) nor hERG (IC50 > 100 μM) inhibition. |
In vivo | Enarodustat (1 and 3 mg/kg, p.o., in rats) treatment increases hemoglobin levels in a dose-dependent manner. |
Synonyms | JTZ-951 |
CAS No. | 1262132-81-9 |
Chemical Formula | C17H16N4O4 |
Molecular Weight | 340.339 |
Solubility | DMSO: 83.33 mg/mL (244.85 mM), Need ultrasonic |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom